MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Gene editing-based therapeutic strategies grant the power to override cell machinery and
alter faulty genes contributing to disease development like cancer. Nowadays, the principal …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

The underlying cause of cancer is genetic disruption, so gene editing technologies,
particularly CRISPR/Cas systems can be used to go against cancer. The field of gene …

Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a
life expectancy comparable to that of the general population thanks to the use of tyrosine …

The current scientific literature has extensively explored the potential role of proteasome
inhibitors (PIs) in the NF-κB pathway of leukemia and lymphoma. The ubiquitin-proteasome …

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are
e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) …

Chronic myeloproliferative neoplasms (MPNs) are hematopoietic stem cell neoplasms with
driver events including the BCR-ABL1 translocation leading to a diagnosis of chronic …

Chronic myeloid leukaemia (CML) is caused by BCR:: ABL1. Tyrosine kinase-inhibitors
(TKIs) are the initial therapy. Several organizations have reported milestones to evaluate …

Chromosomal translocations are the main etiological factor of hematologic malignancies.
These translocations are generally the consequence of aberrant DNA double-strand break …